N-benzyl-4,5-dimethyl-1,3-thiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-benzyl-4,5-dimethyl-1,3-thiazol-2-amine
• 英文别名: N-benzyl-4,5-dimethylthiazol-2-amine；2-benzylamino-4,5-dimethylthiazole
• 化学式: C₁₂H₁₄N₂S
• mdl: MFCD05790562
• 分子量: 218.323
• InChiKey: XDMZYNNHOSXOJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-4,5-二甲基噻唑 、 苯甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 8.5h， 以39%的产率得到N-benzyl-4,5-dimethyl-1,3-thiazol-2-amine
  参考文献：
  名称：

  [EN] SMALL MOLECULE MODULATORS OF MHC-I
  [FR] MODULATEURS À PETITES MOLÉCULES DU CMH-1

  摘要：

  本公开的发明是能够治疗病毒感染的化合物的实施例。例如，这些化合物能够通过作为免疫调节剂来抑制病毒对主要组织相容性复合物I（MHC-I）的降调，从而治疗、治愈或根除病毒感染（例如HIV感染）。更具体地，本公开涉及在治疗感染病毒的患者中使用杂环芳基化合物或其盐或类似物。所公开的化合物可以单独使用或与其他药理活性剂联合使用，以治疗、治愈或根除病毒，特别是在患有持续潜伏病毒感染的患者中。在某些实施例中，所公开的化合物可以单独使用或与其他药理活性剂联合使用，促进潜伏细胞中病毒产生的重新激活和这些细胞的根除。

  公开号：

  WO2019213295A1

文献信息

• Condensation of thiourea derivatives with carbonyl compounds: one-pot synthesis of N-alkyl-1,3-thiazol-2-amines and of 3-alkyl-1,3-thiazolimines
  作者：Carla Boga、Luciano Forlani、Cristian Silvestroni、Anna Bonamartini Corradi、Paolo Sgarabotto

  DOI：10.1039/a809086f

  日期：——

  The reactions of ketones and N-substituted thioureas, in the presence of HCl (or HBr) and DMSO afford mixtures of the title compounds which are easily separated on a silica gel column. This method avoids the classical use of α-haloketones. The mechanism of these reactions involves the enolization of ketones and the activation of thiourea sulfur, probably by oxygen transfer from DMSO.

  在HCl（或HBr）和DMSO的存在下，酮与N-取代的硫脲的反应提供了易于在硅胶柱上分离的标题化合物的混合物。该方法避免了传统的α-卤代酮的使用。这些反应的机理可能涉及酮的烯化和硫脲硫的活化，这可能是通过从DMSO转移氧来实现的。
• One pot synthesis using supported reagents system KSCN/SiO2–RNH3OAc/Al2O3: synthesis of 2-aminothiazoles and N-allylthioureas
  作者：Tadashi Aoyama、Sumiko Murata、Izumi Arai、Natsumi Araki、Toshio Takido、Yoshitada Suzuki、Mitsuo Kodomari

  DOI：10.1016/j.tet.2006.01.075

  日期：2006.4

  A simple and efficient method has been developed for the synthesis of 2-aminothiazoles and N-allylthioureas from commercially available materials in one pot by using a supported reagents system, KSCN/SiO2-RNH3OAc/Al2O3, in which alpha-halo ketone reacts first KSCN/SiO2 and the product, alpha.-thiocyanatoketone, reacts with RNH3OAc/Al2O3 to give the final product, 2-aminothiazoles, in good yield and allyl bromide reacts with KSCN/SiO2 and the product, allyl isothiocyanate, reacts with RNH3OAc/Al2O3 to give N-allylthiourea. (c) 2006 Elsevier Ltd. All rights reserved.
• SMALL MOLECULE MODULATORS OF MHC-I
  申请人：RetroVirox, Inc.

  公开号：US20220411419A1

  公开（公告）日：2022-12-29

  The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.
• [EN] SMALL MOLECULE MODULATORS OF MHC-I<br/>[FR] MODULATEURS À PETITES MOLÉCULES DU CMH-1
  申请人：RETROVIROX INC

  公开号：WO2019213295A1

  公开（公告）日：2019-11-07

  The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.

  本公开的发明是能够治疗病毒感染的化合物的实施例。例如，这些化合物能够通过作为免疫调节剂来抑制病毒对主要组织相容性复合物I（MHC-I）的降调，从而治疗、治愈或根除病毒感染（例如HIV感染）。更具体地，本公开涉及在治疗感染病毒的患者中使用杂环芳基化合物或其盐或类似物。所公开的化合物可以单独使用或与其他药理活性剂联合使用，以治疗、治愈或根除病毒，特别是在患有持续潜伏病毒感染的患者中。在某些实施例中，所公开的化合物可以单独使用或与其他药理活性剂联合使用，促进潜伏细胞中病毒产生的重新激活和这些细胞的根除。